Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | LAG-3: a promising biomarker in cancer

Lymphocyte activation gene 3 (LAG-3) is a recently discovered cell surface molecule which shows promise as a biomarker in cancer patients. Paolo Ascierto, MD from the National Tumour Institute Fondazione G. Pascale, Naples, Italy speaks to us from the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain about the future of LAG-3 in cancer treatments, and tells us the benefits of an improved understanding of tumor microenvironments.